Overexpression pattern, function, and clinical value of proteasome 26S subunit non-ATPase 6 in hepatocellular carcinoma

Figure 1 Flowchart for the collection of proteasome 26S subunit non-ATPase 6 bulk RNA-Sequencing datasets from hepatocellular carcinoma tissues. HCC: Hepatocellular carcinoma; TCGA: The Cancer Genome Atlas; GTEx: Genotype-Tissue Expression; GEO: Gene Expression Omnibus; ICGA: International Cancer Genome Consortium; PSMD6: Proteasome 26S subunit non-ATPase 6.

Figure 2 Qualitative evaluation of proteasome 26S subunit non-ATPase 6 protein expression in hepatocellular carcinoma and non-hepatocellular carcinoma tissues. A and B: Hepatocellular carcinoma (HCC) tissue; C and D: Non-HCC tissue.

Figure 3 Semi-quantitative evaluation of proteasome 26S subunit non-ATPase 6 protein expression in hepatocellular carcinoma and non-hepatocellular carcinoma tissues. A and B: Semi-quantitative comparison of proteasome 26S subunit non-ATPase 6 (PSMD6) protein expression levels between HCC tissues and non-HCC tissues from institutions; C and D: Evaluation of the ability of highly expressed PSMD6 from institutions A and B to identify HCC tissues. HCC: Hepatocellular carcinoma; PSMD6: Proteasome 26S subunit non-ATPase 6.

Figure 4 Proteasome 26S subunit non-ATPase 6 mRNA and protein have significant overexpression patterns in hepatocellular carcinoma tissues. SMD: Standardised mean difference.

Figure 5 Proteasome 26S subunit non-ATPase 6 standardised mean difference reliability test. A: Forest plot of sensitivity analysis of proteasome 26S subunit non-ATPase 6 (PSMD6) standardised mean difference (SMD); B: Funnel plot of publication bias test of PSMD6 SMD. SMD: Standardised mean difference.

Figure 6 Gene knockout effect score of proteasome 26S subunit non-ATPase 6 in hepatocellular carcinoma cell lines. PSMD6: Proteasome 26S subunit non-ATPase 6.

Figure 7 Evaluation of the potential molecular biological mechanisms of proteasome 26S subunit non-ATPase 6 in hepatocellular carcinoma tissues. A: Gene Ontology enrichment analysis; B: Kyoto Encyclopedia of Genes and Genomes enrichment analysis.

Figure 8 Correlation analysis between drug sensitivity of tumour targeted therapy drugs and proteasome 26S subunit non-ATPase 6 mRNA expression level in hepatocellular carcinoma tissues. PSMD6: Proteasome 26S subunit non-ATPase 6.

Figure 9 Construction of molecular docking model between proteasome 26S subunit non-ATPase 6 protein and small molecule compounds. A: Sepantronium bromide; B: ML323; C: GDC0810.

Figure 10  Sensitivity and specificity analysis of proteasome 26S subunit non-ATPase 6 mRNA and protein in identifying hepatocellular carcinoma tissues. A: Summary receiver operating characteristic curve; B: Forest plot of sensitivity and specificity. ROC: Receiver operating characteristic curve; sROC: Summary receiver operating characteristic curve.

Figure 11  Evaluation of the ability of proteasome 26S subunit non-ATPase 6 mRNA and protein expression levels to identify hepatocellular carcinoma tissues. A: Forest plot of likelihood ratio; B: Forest plot of diagnostic score and odds ratio.